Under one in 10 individuals who could benefit from obesity jabs such as Wegovy can access them, caution the World Health Organization as it issues its initial guidance on the drugs.
Given in excess of 1,000,000,000 individuals worldwide now classified as obese, it is calling for increased and just availability to these injectable treatments.
Based on projections, more than two billion are projected to be obese by 2030 unless action is taken.
"Our new guidelines recognises that obesity is a chronic disease that can be addressed with holistic and lifelong care," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are major obstacles to broad access to the injections that can aid individuals in losing considerable weight, explains the agency.
Weight-Loss Drug Shortage
Even in the current most optimistic case, the supply of GLP-1 therapies might only reach approximately 100 million people – under 10% of eligible patients, according to the health organization.
The advice calls on countries and companies to expand access, through strategies like voluntary licensing.
A patent on the active ingredient – the core component of the drug Wegovy – is due to expire in a number of nations in 2026.
The Way Weight-Loss Injections Function
The injections imitate a natural hormone to slow digestion, suppress the appetite and boost the sense of being full so people consume fewer calories.
People commonly start to lose weight after several weeks of starting on the regular doses.
Research suggests patients may see weight return within a year of discontinuing the treatment, when their usual hunger come back.
Being above a healthy weight elevates your likelihood for experiencing medical conditions, including type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight impacts individuals in countries worldwide and was linked to millions of deaths worldwide in 2024, per the WHO.
